

TABLE OF CONTENTS

ACKNOWLEDGEMENTS	i
LIST OF TABLES	xii
LIST OF FIGURES	xvi
LIST OF APPENDICES	xvii
LIST OF ABBREVIATIONS AND ACRONYMS	xix
EXECUTIVE SUMMARY	ES-1
GENERAL INTRODUCTION	GI-1

**FETAX FOR HUMAN DEVELOPMENTAL HAZARD
IDENTIFICATION**

1.0 Introduction and Rationale of FETAX.....	1-1
1.1 Scientific Basis for the Use of FETAX.....	1-1
1.2 Intended Uses of FETAX.....	1-1
1.2.1 Intended Regulatory Uses and Rationale	1-1
1.2.2 Currently Accepted Teratogenicity/Developmental Toxicity Test Methods.....	1-2
1.2.3 The Use of FETAX to Assess Potential Human Teratogenic Hazards.....	1-4
1.2.4 Intended Range of Chemicals Amenable to Test and Limits According to Physico-Chemical Factors	1-4
1.3 Section 1 Conclusions	1-5
2.0 FETAX Test Method Protocol	2-1
2.1 Standard Detailed Protocol.....	2-1
2.1.1 Materials, Equipment, and Supplies	2-2
2.1.2 Detailed Procedures for FETAX.....	2-3
2.1.3 Dose-Selection Procedures—Range-Finding Test.....	2-8
2.1.4 Endpoints Measured.....	2-9
2.1.5 Duration of Exposure	2-10
2.1.6 Known Limits of Use	2-10
2.1.7 Nature of the Responses Assessed.....	2-10
2.1.8 Appropriate Vehicle, Negative, and Positive Controls	2-10
2.1.9 Acceptable Range of Negative and Positive Control Responses	2-13
2.1.10 Data Collection.....	2-13
2.1.11 Data Storage Media.....	2-14
2.1.12 Measures of Variability.....	2-14
2.1.13 Statistical and Non-Statistical Methods	2-15

2.1.14	Decision Criteria	2-16
2.1.15	Test Report Information	2-17
2.2	Commonly Used Variations in the FETAX Standard Protocol and Rationale.....	2-20
2.3	Basis for Selection of FETAX.....	2-21
2.4	Confidentiality of Information	2-21
2.5	Basis for FETAX Decision Criteria	2-21
2.6	Basis for Numbers of Replicates and Repeat Tests in FETAX.....	2-22
2.7	Validation Study Based Modifications to the Standard Protocol.....	2-23
2.8	Section 2 Conclusions	2-24
3.0	Characterization of Substances Tested in FETAX.....	3-1
3.1	Rationale for Chemicals/Products Selected for FETAX Validation Studies	3-1
3.2	Rationale for the Numbers of Chemicals/Products Tested in FETAX.....	3-3
3.3	Description of Chemical and Product Classes Evaluated in FETAX	3-3
3.4	Coding Used in FETAX Validation Studies	3-5
3.5	FETAX-Tested Substances in the Smith et al. (1983) List of Candidate Substances/Conditions for <i>In Vitro</i> Teratogenesis Test Validation	3-5
3.6	Section 3 Conclusions	3-8
4.0	Reference Data Used for an Assessment of FETAX Performance Characteristics	4-1
4.1	Description of Laboratory Mammal and Human Reference Data Sources.....	4-1
4.2	Laboratory Mammal Reference Data.....	4-2
4.3	Availability of Original Laboratory Mammal Reference Test Data	4-3
4.4	Laboratory Mammal Reference Data Quality	4-3
4.5	Availability and Use of Human Teratogenicity Data.....	4-3
4.6	Section 4 Conclusions	4-4
5.0	FETAX Test Method Data and Results.....	5-1
5.1	Availability of Detailed FETAX Protocol.....	5-1
5.2	Availability of Original and Derived FETAX Data	5-1
5.3	Statistical Approach used to Evaluate FETAX Data	5-1
5.4	FETAX Test Results for Individual Substances.....	5-2
5.4.1	FETAX Test Results Without Metabolic Activation	5-3
5.4.2	FETAX Test Results With Metabolic Activation	5-3
5.5	FETAX Test Results With Binary Mixtures	5-3
5.6	Use of Coded Chemicals and Compliance with GLP Guidelines	5-7
5.7	Availability of Non-Audited FETAX Data.....	5-7
5.8	Section 5 Conclusions	5-8

6.0	Performance Characteristics of FETAX	6-1
6.1	Performance Characteristics of FETAX compared to Combined Rat, Mouse, and Rabbit Teratogenicity Test Results	6-2
6.1.1	Performance Characteristics of FETAX, Without Metabolic Activation, compared to Combined Rat, Mouse, and Rabbit Teratogenicity Test Results	6-3
6.1.2	Performance Characteristics of FETAX, With Metabolic Activation, compared to Combined Rat, Mouse, and Rabbit Teratogenicity Test Results.....	6-6
6.1.3	Performance Characteristics of FETAX, With and Without Metabolic Activation, compared to Combined Rat, Mouse, and Rabbit Teratogenicity Test Results	6-10
6.1.4	Performance Characteristics of FETAX, With and Without Metabolic Activation, compared to Combined Rat, Mouse, or Rabbit Teratogenicity Test Results by Chemical and Product Class.....	6-13
6.2	Performance Characteristics of FETAX compared to Individual Rat, Mouse, or Rabbit Species Teratogenicity Test Results	6-20
6.2.1	Performance Characteristics of FETAX, Without Metabolic Activation, compared to Individual Rat, Mouse, or Rabbit Species Teratogenicity Test Results	6-21
6.2.2	Performance Characteristics of FETAX, With Metabolic Activation, compared to Individual Rat, Mouse, or Rabbit Species Teratogenicity Test Results.....	6-24
6.2.3	Performance Characteristics of FETAX, With and Without Metabolic Activation, compared to Individual Rat, Mouse, or Rabbit Species Teratogenicity Test Results	6-26
6.3	Performance Characteristics of FETAX compared to Human Teratogenicity Study Results	6-29
6.3.1	Performance Characteristics of FETAX, Without Metabolic Activation, compared to Human Teratogenicity Study Results.....	6-29
6.3.2	Performance Characteristics of FETAX, With Metabolic Activation, compared to Human Teratogenicity Study Results.....	6-33
6.3.3	Performance of FETAX, With and Without Metabolic Activation, compared to Human Teratogenicity Study Results	6-36

6.3.4	Performance Characteristics of FETAX, With and Without Metabolic Activation, compared to Human Teratogenicity Study Results by Chemical and Product Class	6-40
6.4	Performance Characteristics of Rat, Mouse, and/or Rabbit Teratogenicity Test Results compared to Human Teratogenicity Study Results	6-43
6.5	FETAX Results Discordant with Reference Laboratory Mammal or Human Teratogenicity Study Results	6-45
6.6	NICEATM Analysis of FETAX Decision Criterion.....	6-47
6.6.1	Evaluation for the Optimal FETAX Single Decision Criterion	6-48
6.6.1.1	Combined Rat, Mouse, and Rabbit Teratogenicity Test Results	6-49
6.6.1.2	Human Teratogenicity Study Results	6-52
6.6.2	Characteristic Malformations Induced in <i>X. laevis</i> Embryos	6-55
6.6.3	Evaluation of Growth Inhibition	6-59
6.6.4	The Use of Confidence Intervals.....	6-60
6.6.5	Performance of FETAX with Metabolic Activation	6-60
6.7	Strengths and Limitations of FETAX in Terms of Performance Characteristics	6-64
6.8	Data Interpretation Issues	6-66
6.9	Section 6 Conclusions	6-67
7.0	Test Method Reliability (Repeatability/Reproducibility)	7-1
7.1	Selection Rationale for Substances Used to Evaluate Test Method Reliability.....	7-1
7.2	Assessment of Test Method Reliability (Repeatability and Reproducibility).....	7-1
7.2.1	FETAX Phase I Validation Study (Bantle et al., 1994a)	7-2
7.2.2	FETAX Phase II Validation Study (Bantle et al., 1994b)	7-5
7.2.3	FETAX Phase III.1 Validation Study (Bantle et al., 1996)	7-8
7.2.4	FETAX Phase III.2 Validation Study (Fort et al., 1998)	7-11
7.2.5	FETAX Phase III.3 Validation Study (Bantle et al., 1999)	7-15
7.3	Additional Evaluations Conducted by NICEATM	7-27
7.3.1	Inter-Laboratory CV Data for All FETAX Validation Studies.....	7-27
7.3.2	Inter- and Intra-Laboratory Reliability of FETAX Studies on Caffeine	7-31
7.3.3	Assessment of the Effect of Malformation Identification Expertise on FETAX Performance	7-31

7.4	Summary of Historical Positive and Negative Control Data	7-35
7.5	Limitations of FETAX in Regard to Test Method Reliability (as determined by NICEATM).....	7-37
7.6	Data Interpretation Issues.....	7-37
7.7	Section 7 Conclusions	7-40
8.0	Test Method Data Quality	8-1
8.1	Extent of Adherence to GLP Guidelines.....	8-1
8.2	Results of Data Quality Audits.....	8-1
8.3	Impact of GLP Deviations and/or Data Audit Non-Compliance	8-1
8.4	Section 8 Conclusions	8-2
9.0	Other Scientific Reports and Reviews	9-1
9.1	Availability of Other FETAX Data	9-1
9.2	Conclusions of Other Peer Reviews	9-1
9.3	Section 9 Conclusions	9-3
10.0	Animal Welfare Considerations	10-1
10.1	Extent to which FETAX Will Reduce, Refine, or Replace Animal Use for Human Developmental Hazard Assessment	10-1
10.2	Section 10 Conclusions	10-2
11.0	Other Considerations.....	11-1
11.1	Test Method Transferability	11-1
11.1.1	Facilities and Major Fixed Equipment	11-1
11.1.2	Required Level of Personnel Training and Expertise	11-1
11.1.3	General Availability of Necessary Equipment and Supplies	11-2
11.2	Assay Costs	11-2
11.3	Time Needed to Conduct the Test.....	11-2
11.4	Potential Effect of Tetraploidy on the Use of <i>X. laevis</i> in FETAX	11-3
11.5	<i>Xenopus</i> Microarray Technology	11-3
11.6	Other <i>In Vitro</i> Assays for Mammalian Developmental Hazard Identification.....	11-5
11.7	Section 11 Conclusions	11-8

FETAX FOR ECOTOXOLOGICAL HAZARD ASSESSMENT USING WATER/SOIL/SEDIMENT SAMPLES

12.0	Introduction and Rationale for the Use of FETAX in Assessing Developmental Hazards in Water/Soil/Sediment Samples	12-1
12.1	Scientific Basis for the Use of FETAX	12-1
12.2	Intended Uses of FETAX	12-2
12.2.1	Intended Regulatory Uses and Rationale	12-2

12.2.2. Currently Accepted Water/Soil/Sediment Developmental Toxicity Testing Methods	12-2
12.2.3 Ability of FETAX to Assess Potential Developmental Hazards in Water/Soil/Sediment Samples.....	12-3
12.2.4 Intended Range of Water/Soil/Sediment Samples Amenable to Test and Limits According to Physico—Chemical Factors	12-3
12.3 Section 12 Conclusions	12-4
13.0 FETAX Test Method Protocol	13-1
13.1 Standard Detailed Protocol.....	13-1
13.1.1 Materials, Equipment, and Supplies.....	13-1
13.1.2 Detailed Procedures for FETAX	13-1
13.1.3 Dose-Selection Procedures—Screening Test.....	13-3
13.1.4 Endpoints Measured	13-3
13.1.5 Duration of Exposure	13-3
13.1.6 Known Limits of Use	13-3
13.1.7 Nature of the Responses Assessed	13-4
13.1.8 Appropriate Vehicle, Negative, and Positive Controls	13-4
13.1.9 Acceptable Range of Negative and Positive Control Responses	13-4
13.1.10 Data Collection.....	13-4
13.1.11 Data Storage Media.....	13-4
13.1.12 Measures of Variability	13-5
13.1.13 Statistical and Non-Statistical Methods	13-5
13.1.14 Decision Criteria.....	13-5
13.1.15 Test Report Information	13-6
13.2 Commonly Used Variations in the FETAX Standard Protocol and Rationale	13-6
13.2.1 Use of Alternative Species	13-6
13.2.2 Additional Data and Alternative Exposure Protocols	13-7
13.3 Basis for Selection of FETAX.....	13-7
13.4 Confidentiality of Information	13-7
13.5 Basis for FETAX Decision Criteria	13-7
13.6 Basis for Numbers of Replicates and Repeat Tests in FETAX.....	13-7
13.7 Validation Study Based Modifications to the Standard Protocol.....	13-8
13.8 Section 13 Conclusions	13-8
14.0 Characterization of Environmental Water/Soil/Sediment Samples Tested in FETAX	14-1
14.1 Rationale for Water/Soil/Sediment Samples Selected for FETAX Validation Studies	14-1
14.2 Rationale for the Numbers of Water/Soil/Sediment Samples Tested in FETAX Validation Studies.....	14-1
14.3 Description of Chemical/Product Classes Evaluated in FETAX	14-1
14.4 Coding Used in FETAX Validation Studies	14-1

14.5 Section 14 Conclusions	14-2
15.0 Reference Data Used for an Assessment of FETAX Performance	
Characteristics	15-1
15.1 Description of Available Reference Data Sources	15-1
15.2 Reference Data	15-1
15.3 Availability of Original Reference Test Data.....	15-1
15.4 Reference Data Quality	15-2
15.5 Availability and Use of Human Teratogenicity Data.....	15-2
15.6 Section 15 Conclusions	15-2
16.0 FETAX Test Method Data and Results.....	16-1
16.1 Availability of a Detailed FETAX Protocol.....	16-1
16.2 Availability of Original and Derived FETAX Data	16-1
16.3 Statistical and Non-Statistical Approaches used to Evaluate FETAX Data.....	16-1
16.4 FETAX Test Results for Individual Water/Soil/Sediment Samples Evaluated to Assess Developmental Toxicity	16-1
16.4.1 FETAX Testing with Water/Sediment Samples	16-2
16.4.2 FETAX Testing with Soil Samples	16-4
16.4.3 FETAX Testing with Other Environmental Samples.....	16-7
16.5 Use of Coded Environmental Samples and Compliance with GLP Guidelines	16-8
16.6 Availability of Non-Audited FETAX Data.....	16-9
16.7 Section 16 Conclusions	16-9
17.0 Performance Characteristics of FETAX with Water/Soil/Sediment Samples	17-1
18.0 Test Method Reliability (Repeatability/Reproducibility).....	18-1
18.1 Summary of Historical Positive and Negative Control Data	18-1
18.2 Limitations of FETAX in Regard to Test Method Reliability	18-1
18.3 Data Interpretation Issues.....	18-1
18.4 Section 18 Conclusions	18-1
19.0 Test Method Data Quality	19-1
19.1 Extent of Adherence to GLP Guidelines	19-1
19.2 Results of Data Quality Audits.....	19-1
19.3 Impact of GLP Deviations and/or Data Audit Non-Compliance	19-1
19.4 Section 8 Conclusions	19-1
20.0 Other Scientific Reports and Reviews.....	20-1
20.1 Availability of Other Relevant FETAX Data.....	20-1
20.2 Conclusions of Other Peer Reviews.....	20-1
20.3 Section 20 Conclusions	20-1

21.0 Animal Welfare Considerations	21-1
21.1 Extent to which FETAX Will Reduce, Refine, or Replace Animal Use for Ecotoxicological Hazard Assessment using Water/Soil/Sediment Samples	21-1
22.0 Other Considerations	22-1
22.1 Test Method Transferability	22-1
22.1.1 Facilities and Major Fixed Equipment	22-1
22.1.2 Required Level of Personnel Training and Expertise	22-1
22.1.3 General Availability of Necessary Equipment and Supplies	22-1
22.2 Assay Costs	22-1
22.3 Time Needed to Conduct the Test	22-2
22.4 Section 22 Conclusions	22-2
23.0 Other Applications for <i>Xenopus</i>	23-1
23.1 <i>Xenopus</i> Tail Resorption Assay	23-1
23.2 <i>Xenopus</i> Vitellogenin Assay	23-2
23.3 Evaluation of Reproductive Toxicity	23-3
23.4 <i>Xenopus</i> Limb Bud Assay	23-4
23.5 Section 23 Conclusions	23-4
24.0 References	24-1